Abstract
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is characterized by recurrent episodes of inflammation with fever, abdominal pain, chest pain, rash, myalgia, arthralgia, conjunctivitis, and periorbital edema. This condition is a rare autosomal dominant disease that is strongly associated with heterozygous mutations in the tumor necrosis factor (TNF) receptor super family 1A (TNFRSF1A) gene. This condition is believed to be more common in Western countries than in Asian countries, and the AA amyloidosis rate for European countries is estimated to be 10%. Herein, we report the case of a 14-year-old girl with recurrent fever and arthralgia with inflammatory marker elevation for 10 years. After extensive investigation of the infectious etiology with negative results and similar phenomenon observed within her family, the diagnosis of TRAPS was made based on next-generation sequencing, which revealed a T50M mutation; she was also sensitive to corticosteroids. Although none of our TRAPS patients developed AA amyloidosis, we suggest the continual monitoring of urinalysis results and serum amyloid A concentrations during long-term follow-up. Moreover, we also reviewed the related literature and found no Asian patients who had developed AA amyloidosis.
Similar content being viewed by others
References
Rigante D, Vitale A, Lucherini OM, Cantarini L (2014) The hereditary autoinflammatory disorders uncovered. Autoimmun Rev 13(9):892–900. https://doi.org/10.1016/j.autrev.2014.08.001
Almeida de Jesus A, Goldbach-Mansky R (2013) Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol 147(3):155–174. https://doi.org/10.1016/j.clim.2013.03.016
Ueda N, Ida H, Washio M, Miyahara H, Tokunaga S, Tanaka F, Takahashi H, Kusuhara K, Ohmura K, Nakayama M, Ohara O, Nishikomori R, Minota S, Takei S, Fujii T, Ishigatsubo Y, Tsukamoto H, Tahira T, Horiuchi T (2016) Clinical and genetic features of patients with TNFRSF1A variants in Japan: findings of a nationwide survey. Arthritis Rheumatol 68(11):2760–2771. https://doi.org/10.1002/art.39793
Holzinger D, Kessel C, Omenetti A, Gattorno M (2015) From bench to bedside and back again: translational research in autoinflammation. Nat Rev Rheumatol 11(10):573–585. https://doi.org/10.1038/nrrheum.2015.79
Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L, Frenkel J, Anton J, Kone-Paut I, Cattalini M, Bader-Meunier B, Insalaco A, Hentgen V, Merino R, Modesto C, Toplak N, Berendes R, Ozen S, Cimaz R, Jansson A, Brogan PA, Hawkins PN, Ruperto N, Martini A, Woo P, Gattorno M, Paediatric Rheumatology International Trials Organisation (PRINTO), the EUROTRAPS and the Eurofever Project (2014) The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 73(12):2160–2167. https://doi.org/10.1136/annrheumdis-2013-204184
McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97(1):133–144. https://doi.org/10.1016/S0092-8674(00)80721-7
Lane T, Loeffler JM, Rowczenio DM, Gilbertson JA, Bybee A, Russell TL, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ (2013) AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 65(4):1116–1121. https://doi.org/10.1002/art.37827
Lainka E, Neudorf U, Lohse P, Timmann C, Stojanov S, Huss K, von Kries R, Niehues T (2009) Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics. Rheumatology (Oxford) 48(8):987–991. https://doi.org/10.1093/rheumatology/kep140
Chen YJ, Yu HH, Yang YH, Lau YL, Lee WI, Chiang BL (2014) Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: a case report and review of the literature. J Microbiol Immunol Infect 47(6):550–554. https://doi.org/10.1016/j.jmii.2012.07.003
Federici S, Sormani MP, Ozen S, Lachmann HJ, Amaryan G, Woo P, Koné-Paut I, Dewarrat N, Cantarini L, Insalaco A, Uziel Y, Rigante D, Quartier P, Demirkaya E, Herlin T, Meini A, Fabio G, Kallinich T, Martino S, Butbul AY, Olivieri A, Kuemmerle-Deschner J, Neven B, Simon A, Ozdogan H, Touitou I, Frenkel J, Hofer M, Martini A, Ruperto N, Gattorno M, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Eurofever Project (2015) Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 74(5):799–805. https://doi.org/10.1136/annrheumdis-2014-206580
Manthiram K, Zhou Q, Aksentijevich I, Kastner DL (2017) The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol 18(8):832–842. https://doi.org/10.1038/ni.3777
Washio M, Nakano T, Kawaguchi Y, Takagi K, Kiyohara C, Tsukamoto H, Tokunaga S, Horiuchi T (2013) Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in Japan: a review of the literature. Mod Rheumatol 23(2):210–217. https://doi.org/10.3109/s10165-012-0737-3
Quillinan N, Mannion G, Mohammad A, Coughlan R, Dickie LJ, McDermott MF et al (2011) Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis 70(9):1692–1693. https://doi.org/10.1136/ard.2010.144279
Cantarini L, Lopalco G, Vitale A, Caso F, Lapadula G, Iannone F, Galeazzi M, Rigante D (2015) Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant. Int J Rheum Dis 18(4):473–475. https://doi.org/10.1111/1756-185X.12521
Schwabe AD, Peters RS (1974) Familial Mediterranean fever in Armenians. Analysis of 100 cases. Medicine (Baltimore) 53(6):453–462. https://doi.org/10.1097/00005792-197411000-00005
ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, Cantarini L, Galeotti C, Grateau G, Hentgen V, Hofer M, Kallinich T, Kone-Paut I, Lachmann HJ, Ozdogan H, Ozen S, Russo R, Simon A, Uziel Y, Wouters C, Feldman BM, Vastert SJ, Wulffraat NM, Benseler SM, Frenkel J, Gattorno M, Kuemmerle-Deschner JB (2015) Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 74(9):1636–1644. https://doi.org/10.1136/annrheumdis-2015-207546
Gattorno M, Obici L, Cattalini M, Tormey V, Abrams K, Davis N, Speziale A, Bhansali SG, Martini A, Lachmann HJ (2017) Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis 76(1):173–178. https://doi.org/10.1136/annrheumdis-2015-209031
Vaitla PM, Radford PM, Tighe PJ, Powell RJ, McDermott EM, Todd I et al (2011) Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 63(4):1151–1155. https://doi.org/10.1002/art.30215
Akasbi N, Soyfoo MS (2015) Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: a case report. Eur J Rheumatol 2(1):35–36. https://doi.org/10.5152/eurjrheumatol.2014.14053
Hosoya T, Mizoguchi F, Hasegawa H, Miura K, Koike R, Kubota T, Miyasaka N, Kohsaka H (2015) A case presenting with the clinical characteristics of tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) without TNFRSF1A mutations successfully treated with tocilizumab. Intern Med 54(16):2069–2072. https://doi.org/10.2169/internalmedicine.54.3371
La Torre F, Muratore M, Vitale A, Moramarco F, Quarta L, Cantarini L (2015) Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatol Int 35(11):1943–1947. https://doi.org/10.1007/s00296-015-3305-2
Yilmaz S, Cinar M, Simsek I, Erdem H, Pay S (2015) Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 54(3):564–565. https://doi.org/10.1093/rheumatology/keu474
Ugurlu S, Hacioglu A, Adibnia Y, Hamuryudan V, Ozdogan H (2017) Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. Orphanet J Rare Dis 12(1):105. https://doi.org/10.1186/s13023-017-0642-0
Acknowledgements
Jinlin Liu was supported by the National Natural Science Foundation of China (No: 81502472), Zhejiang Provincial Natural Science Fund (No: LY18H200002), Zhejiang Provincial Health Bureau (No: 2018KY014), and Outstanding Youth Foundation of Zhejiang Provincial People’s Hospital (No: 2015 A level). Yanxia Chen was supported by the Zhejiang Provincial Health Bureau (No: 2018KY218).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Rights and permissions
About this article
Cite this article
Chen, Y., Huang, X., Zheng, S. et al. Recurrent fever and arthralgia as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Chinese girl: a case report and review of the literature. Clin Rheumatol 37, 1433–1438 (2018). https://doi.org/10.1007/s10067-018-4023-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-018-4023-4